Literature DB >> 19779934

Association of clinicopathological features with UbcH10 expression in colorectal cancer.

Shimin Chen1, Yingjian Chen, Chengjin Hu, Hongbiao Jing, Yongcheng Cao, Xianxi Liu.   

Abstract

PURPOSE: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme, and its overexpression has been demonstrated in a variety of malignancies. The aim of this study is to investigate the association of UbcH10 gene expression with the carcinogenesis and tumor progression of colorectal cancer.
METHODS: The expression levels of UbcH10 in human malignant colorectal carcinoma tissues and their adjacent normal tissues were examined using real-time quantitative RT-PCR and immunohistochemical analysis. The correlations of UbcH10 expression to the clinicalpathologic characteristics of the colorectal cancer were analyzed. Cell proliferation and Matrigel invasion assays were performed in HT-29 cells transfected with UbcH10 expression plasmid pcDNA3.1-UbcH10, UbcH10 RNA interference vector pUbcH10-RNAi as well as their control vectors.
RESULTS: Our study demonstrated that the expression of UbcH10 in colorectal carcinoma tissues was significantly higher than that in non-cancerous tissues (P < 0.01), and the UbcH10 overexpression was related to the degree of tumor differentiation and lymph node metastasis of colorectal cancer patients (P < 0.05). In vitro, the overexpression of UbcH10 promoted cell proliferation and tumor invasiveness, but the downregulation of UbcH10 expression significantly reduced the growth rate and the invasiveness activity of tumor cell line.
CONCLUSIONS: Our study suggests that the overexpression of UbcH10 gene plays a critical role in the carcinogenesis and tumor progression of colorectal cancer. It may be a new marker in diagnosis and prognosis of colorectal cancer, and the inhibition of UbcH10 may be a therapeutic potential for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779934     DOI: 10.1007/s00432-009-0672-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10.

Authors:  Yaqiong Lin; William C Hwang; Ravi Basavappa
Journal:  J Biol Chem       Date:  2002-04-01       Impact factor: 5.157

3.  Before and after the spindle assembly checkpoint--an APC/C point of view.

Authors:  Armand de Gramont; Olivier Ganier; Orna Cohen-Fix
Journal:  Cell Cycle       Date:  2006-09-15       Impact factor: 4.534

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

5.  E2-C, a cyclin-selective ubiquitin carrier protein required for the destruction of mitotic cyclins.

Authors:  A Aristarkhov; E Eytan; A Moghe; A Admon; A Hershko; J V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  Identification of a novel ubiquitin-conjugating enzyme involved in mitotic cyclin degradation.

Authors:  H Yu; R W King; J M Peters; M W Kirschner
Journal:  Curr Biol       Date:  1996-04-01       Impact factor: 10.834

7.  Cell cycle-regulated proteolysis of mitotic target proteins.

Authors:  H Bastians; L M Topper; G L Gorbsky; J V Ruderman
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

8.  Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase.

Authors:  F M Townsley; A Aristarkhov; S Beck; A Hershko; J V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme.

Authors:  Yoshiaki Okamoto; Toshinori Ozaki; Kou Miyazaki; Mineyoshi Aoyama; Masaru Miyazaki; Akira Nakagawara
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

Review 10.  Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma.

Authors:  Daniel Royston; David G Jackson
Journal:  J Pathol       Date:  2009-04       Impact factor: 7.996

View more
  21 in total

1.  Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway.

Authors:  Zhongmian Zhang; Ping Liu; Jian Wang; Tianxiao Gong; Fang Zhang; Jun Ma; Na Han
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

2.  A monoclonal antibody against a potential cancer biomarker, human ubiquitin-conjugating enzyme E2.

Authors:  Hongyan Du; Ligang Jie; Weiwen Xu; Yingsong Wu; Tiancai Liu; Ming Li
Journal:  Hybridoma (Larchmt)       Date:  2012-06

3.  Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression.

Authors:  Mohammad Ali Fahmidehkar; Sayed Mohammad Shafiee; Ebrahim Eftekhar; Laleh Mahbudi; Atefeh Seghatoleslam
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

Review 4.  Concise machinery for monitoring ubiquitination activities using novel artificial RING fingers.

Authors:  Kazuhide Miyamoto; Kazuki Saito
Journal:  Protein Sci       Date:  2018-05-03       Impact factor: 6.725

5.  Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.

Authors:  Akhilesh Rawat; Gopisetty Gopal; Ganesharaja Selvaluxmy; Thangarajan Rajkumar
Journal:  Cell Oncol (Dordr)       Date:  2013-09-27       Impact factor: 6.730

6.  CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.

Authors:  Hongyan Wang; Chunpeng Zhang; Anna Rorick; Dayong Wu; Ming Chiu; Jennifer Thomas-Ahner; Zhong Chen; Hongyan Chen; Steven K Clinton; Kenneth K Chan; Qianben Wang
Journal:  Cancer Res       Date:  2011-05-18       Impact factor: 12.701

Review 7.  Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.

Authors:  Zhonglin Hao; Hui Zhang; John Cowell
Journal:  Tumour Biol       Date:  2011-12-16

8.  UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.

Authors:  Shang-Ze Li; Yang Song; Hui-Hui Zhang; Bing-Xue Jin; Yi Liu; Wen-Bin Liu; Xiao-Dong Zhang; Run-Lei Du
Journal:  Sci Rep       Date:  2014-11-07       Impact factor: 4.379

9.  High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.

Authors:  Zhihua Shen; Xiaofan Jiang; Chao Zeng; Shaojiang Zheng; Botao Luo; Yumei Zeng; Ranran Ding; Hanguo Jiang; Qiyi He; Junli Guo; Wei Jie
Journal:  BMC Cancer       Date:  2013-04-15       Impact factor: 4.430

10.  The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data.

Authors:  Chao-Hua Mo; Li Gao; Gang Chen; Zhen-Bo Feng; Xiao-Fei Zhu; Kang-Lai Wei; Jing-Jing Zeng
Journal:  Cancer Cell Int       Date:  2017-09-25       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.